细胞色素P450 酶基因多态性的研究进展及临床意义

摘要/Abstract

摘要： 细胞色素P450 (cytochrome P450, CYP) 是重要的药物代谢酶, 参与催化多种内源和外源化合物, 特别是多种临床药物的生物转化。CYP 存在广泛的基因多态性和表型多态性, 体现在个体对于各种化合物的代谢存在明显差异。本文综述了CYP 的基因多态性、与药物代谢相关的CYP 各亚型的特点和临床意义, 主要目的是合理解释和预测临床上药物间相互作用和药物不良反应等, 为实现临床个体化给药提供科学依据。

关键词: 细胞色素P450, 基因多态性, 药物代谢

Abstract: Cytochrome P450 is the very most important enzyme of drug metabolism.It involves in biotransformation of various endogenous and exogenous compounds, especially for clinical drugs.There are many polymorphisms of gene and phenotype, resulting in significant individual variability of different kinds of compounds.This article reviews the genetic polymorphisms of CYP, the characters and clinical meanings of diverse subgroups that relevant to drug metabolism in recent years.The major object of this article is reasonably explaining and predicting the interaction of clinical drugs and the drug adverse reaction in order to providing scientific evidences for the individual administration in clinic.

Key words: cytochrome P450, genetic polymorphism, drug metabolism

中图分类号:

R969

李纳, 施孝金. 细胞色素P450 酶基因多态性的研究进展及临床意义[J]. 中国临床药理学与治疗学, 2009, 14(10): 1193-1200.

LI Na, SHI Xiao-jin. Research development and clinical significance of genetic polymorphism of CYP450[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1193-1200.

参考文献

[1] Wrighton SA, vardonbradonM, Ring BJ.The human drug metabolizing cytochromes P450[J].J Pharm Biopharm, 1996, 24(5):461-473.
[2] Fujihara J, Shiwaku K, Xue Y, et al.CYP1A2 polymorphism(C>A at position -163) in Ovambos, Koreans and Mongolians[J].Cell Biochem Funct, 2007, 25(5):491-494.
[3] Aklillu E, Carrillo JA, Makonnen E, et al.Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression:Characterization of novel haplotypes with single- nucleotide polymorphisms in intron 1[J].Mol Pharmacol, 2003, 64(3):659-669.
[4] Murayama N, Soyama A, Saito Y, et al.Six novel nonsynonymous CYP1A2 gene polymorphisms:Catalytic activities of the naturally occurring variant enzymes[J].J Pharmacol Exp Ther, 2004, 308(3):1219-1219.
[5] Allorge D, Chevalier D, Lo-Guidice JM, et al.Identifica-Chin J Clin Pharmacol Ther 2009 Oct;14(10) tion of a novel splice-site mutation in the CYP1A2 gene [J].Br J Clin Pharmacol, 2003, 56(3):341-344.
[6] Skarke C, Kirchhof A, Geisslinger G, et al.Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing[J]. Eur J Clin Pharmacol, 2005, 61(12):887-892.
[7] Ghotbi R, Christensen M, Roh HK, et al.Comparisons of CYP1A2 genetic polymorphism, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans [J].Eur J Clin Pharmacol, 2007, 63(6):537-546.
[8] Grabar PB, Rozman B, Tomsic M, et al.Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients[J].Eur J Clin Pharmacol, 2008, 64(9):871-876.
[9] Tay JKX, Tan CH, Chong SA, et al.Functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene and prolonged QTc interval in schizophrenia[J].Prog Neuro- Psychopharmacol Biol Psychiatry, 2007, 31(6):1297-1302.
[10] Obase Y, Shimoda T, Kawano T, et al.Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma[J].Clin Parmacol Ther, 2003, 73(5):468-474.
[11] Kivisto KT, Kroemer HK.Use of probe drugs as predictors of drug metabolism in humans[J].J Clin Pharmacol, 1997, 37(Suppl 1):S40-S48.
[12] DeMorais SM, Wilkinson GR, Blaisdell J, et al.The major genetic defect responsible for the polymorphism of Smephenytoin metabolism in humans[J].J Biol Chem, 1994, 269(22):15419-15422.
[13] DeMorais SM,Wilkinson GR, Blaisdell J, et al.Identification of a new genetic-defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese[J]. Mol Pharmacol, 1994, 46(4):594-598.
[14] Xiao ZS, Goldstein JA, Xie HG, et al.Differences in the incidence of the CYP2C19 polymorphism affecting the Smephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele[J].J Pharmacol Exp Ther, 1997, 281(1):604-609.
[15] Ibeanu GC, Blaisdell J, Ferguson RJ, et al.A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug Smephenytoin[J].J Pharmacol Exp Ther, 1999, 290(2): 635-640.
[16] Yin OQR, Tomlinson B, Chow AHL, et al.Omeprazole as a CYP2C19 Marker in Chinese subjects:Assessment of its gene-dose effect and intrasubject variability [J].J Clin Pharmacol, 2004, 44(6):582-589.
[17] 郑露, 邵建国.CYP2C19 的基因多态性与临床[J].第二军医大学学报, 2007, 28(11):1262-1265.
[18] Rudberg I, Hermann M, Refsum H, et al.Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psy chiatric patients[J].Eur J Clin Pharmacol, 2008, 64(12):1181-1188.
[19] Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J].Clin Pharmacol Ther, 2006, 79(1):103-113.
[20] Sugimoto K, Uno T, Yamazaki H, et al.Limited frequency of the CYP2C19^＊17 allele and its minor role in a Japanese population[J].Br J Clin Pharmacol, 2008, 65(3): 437-439.
[21] King BP,Khan TI, Aithal GP, et al.Up stream and coding region CYP2C9 polymorphisms:correlation with warfarin dose and metabolism[J].Pharmacogenetics, 2004, 14(12):813-822.
[22] Dickmann LJ, Rettie AE, Kneller MB, et al.Identification and functional characterization of a new CYP2C9 variant (CYP2C9^＊5) expressed among African Americans[J]. Mol Pharmacol, 2001, 60(2):382-387.
[23] 李智, 王果, 周宏灏.CYP2C19 基因多态性及其功能意义研究进展[J].中国临床药理学与治疗学,2008, 13(6):601-609.
[24] Xie HG, Prasad HC, Kim RB, et al.CYP2C19 allelic variants: ethnic distribution and functional significance [J]. Adv Drug Deliver Rev, 2002, 54(10):1257-1270.
[25] VanderWeide J, Steijns LS, vanWeeldenMJ, et al.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement[J].Pharmacogenetics, 2001, 11(4):287-291.
[26] 李健, 文思远, 王睿, 等.细胞色素P450 CYP2C9 基因多态性对甲苯磺丁脲代谢动力学的影响[J].药学学报, 2005, 40(8):695-699.
[27] Lindh JD, Holm L, Andersson ML, et al.Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis[J].Eur J Clin Pharmacol, 2009, 65(4):365-375.
[28] Zhang YF, Zhong DF, Si DY, et al.Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype [J].Br J Clin Pharmacol, 2005, 59(1):14-17.
[29] Bae JW, Kim JH, Choi CI, et al.Effect of CYP2C9^＊3 allele on the pharmacokinetics of naproxen in Korean subjects[J].Arch Pharm Res, 2009, 32(2):269-273.
[30] Shimada T, Tsumura F, Yamazaki H, et al.Characterization of (+ -) bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6[J].Pharmacogenetics, 2001, 11(2):143-156.
[31] Evert B, Griese EU, Eichelbaum M.A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine[J].Naunyn Schmiedebergs Arch Pharmacol, 1994, 350(4):434-439.
[32] Sawamura K, Suzuki Y, Someya T, et al.Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine[J].Eur J Clin Pharmacol, 2004, 60(8):553-557.
[33] Yin OP, Shi XJ, Tomlinson B, et al.Effect of CYP2D6^*10 allele on the pharmacokinetics of loratadine in chinese subjects[J].Drug Metab Dispos, 2005, 33(9):1283-1287.
[34] 李芹, 王睿, 郭雅, 等.中国人群CYP2D6 基因多态性对美托洛尔药代动力学的影响[J].中国临床药理学与治疗学, 2008, 13(7):796-802.
[35] Shams MEE, Arneth B, Hiemke C, et al.CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine[J].J Clin Pharm Ther, 2006, 31(5):493-502.
[36] 伍忠銮, 谢红光, 周宏灏.细胞色素P450 2E1 的研究进展[J].中国临床药理学杂志, 1997, 13(1):57-62.
[37] Hu Y, Oscarson M, Johansson I, et al.Genetic polymorphism of human CYP2E1:characterization of two variant alleles[J].Mol Pharmacol, 1997, 51(3):370-376.
[38] Howard LA, Ahluwalia JS, Lin SK, et al.CYP2E1^＊1D regulatory polymorphism:association with alcohol and nicotine dependence[J].Pharmacogenetics, 2003, 13(6): 321-328.
[39] Sata F, Sapone A, Elizondo G, et al.CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:evidence for an allelic variant with altered catalytic activity [J].Clin Pharmacol Ther, 2000, 67(1):48-56.
[40] Fukushima-Uesaka H, Saito Y,Watanabe H, et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J].Hum Mutat, 2004, 23(1):100-108.
[41] Hsieh KP, Lin YY, Cheng CL, et al.Novel mutations of CYP3A4 in Chinese[J].Drug Metab Dispos, 2001, 29(3):268-273.
[42] Wang A, Yu BN, Luo CH, et al.IIe118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients[J]. Eur J Clin Pharmacol, 2005, 60(12):843-848.
[43] Gao Y, Zhang LR, Fu Q.CYP3A4^*1G polymorphism is associated with lipid-lowering efficacy of atorbvastatin but not of simvastatin[J].43] Gao Y, Zhang LR, Fu Q.CYP3A4^*1G polymorphism is associated with lipid-lowering efficacy of atorbvastatin but not of simvastatin[J].Eur J Clin Pharmacol, 2008, 64(9):877-882.
[44] Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al.Phenotype- genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles[J].Biochem Biophys Res Commum, 2005, 338(1):299-305.
[45] 姜敏, 熊玉卿.细胞色素氧化酶P450 3A4 与药物代谢[J].实用临床医学, 2006, 7(11):199-201